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Abstract 
Results of health studies are the foundation for the practice of evidence based 
medicine and public health. Although randomized controlled trials remain the gold 
standard, the appropriate use of quasi-experimental and observational studies can 
provide quality results. Dissemination of clinical trial results in a systematic fashion not 
only facilitates the comparison of trials, but also allows for evaluation of quality. Quality 
clinical trials require careful attention to minimize bias and maximize internal and 
external validity. External validity of clinical trials is directly influenced by the 
generalizability of the trial results. In order for results to be generalizable, study 
populations must be representative of the population of interest; especially the 
population segment that will benefit most from the treatment being studied. Historically, 
clinical trial populations are dominated by white males. Underrepresented populations 
often face barriers to participation. Focused efforts to minimize barriers, such as lack of 
access, poor cultural competence, and financial strain, will increase participation. 
Funding sources and regulatory bodies also influence clinical trial quality by enacting 
policies that promote generalizability. Guidelines presented here will facilitate the 
breakdown of barriers to clinical trial participation leading to diverse participation and 
greater generalizability so that all individuals will benefit from novel interventions.  
 Application of good leadership practice is needed to facilitate the breakdown of barriers 
and promote accrual of underrepresented populations. Ultimately, improving 
generalizability of clinical trial results will provide better information to use as the basis 
of health policy and practice.    
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Introduction 
 Clinical trials are the standard on which evidenced based medicine is centered. 
The gold standard is a randomized double blinded controlled clinical trial. In many 
cases, meeting this gold standard is not feasible, especially in a public health setting 
where other types of trials such as observational and quasi-experimental studies 
dominate. Despite inherent limitations, results from valid clinical trials provide 
knowledge to guide medical and public health practice. Critical evaluation of clinical 
trials is necessary to ensure results are translatable to clinical practice. In fact, funding 
agencies, including the United States federal government, are championing initiatives, 
such as Clinical Translational Science Associations (CTSA), to support the translation of 
basic science research to clinical practice. A number of tools are available to evaluate 
methodological quality of clinical trials. Use of these tools in combination with 
standardized reporting practices will enhance the transition of results to clinical practice. 
Ensuring equity and sound design in a clinical trial while utilizing standardized 
procedures, such as good clinical practice (GCP), provides results that are 
generalizable. However, barriers to participation in trials are extensive and can lead to 
skewed accrual and biased interpretation. The goals of this paper are to examine the 
characteristics of quality clinical trials including an in depth focus on generalizability to 
improve external validity and address disparities. Frequently, clinical trial cohorts are not 
representative of target populations, a fact that is especially troubling when individuals 
that benefit most from the treatment under investigation are underrepresented. This 
paper will highlight the common disparity of underrepresented populations. 
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Designing Clinical Trials of the Highest Possible Validity 
 Choosing the appropriate design is a critical component of a quality clinical trial. 
The hypothesis is a driving factor for design, although mitigating issues such as ethical 
considerations must be included. For example, inclusion of a placebo control when a 
suitable alternative medication is available maybe unethical. While the randomized 
placebo controlled trial is the benchmark, other designs as shown in Table 1 and 2 are 
frequently utilized.  
Table 1: Types of Health studies 
Type of Study Indication(s) for use Pros Cons 
Randomized 
Controlled Trial 
Research question involves 
prevention or treatment, Small 
effect expected, Ethical, Feasible, 
Money is available 
Gold standard, can assess 
causality, maximize internal 
validity, minimize bias 
Expensive, uses 
narrowly selected 
populations, limits 
generalizability 
Quasi-experimental                  
(Non-Randomized 
Trial) 
Research question involves 
assessing intervention, 
Randomized Controlled trial not 
ethical, feasible or too expensive.  
Less expensive, Can 
assess causality, Threats 
to validity can be minimized 
with proper design 
Confounding factors 
Observational 
Studies 
Research question involved 
prevention, treatment or causal 
factor, Moderate or large effect 
expected, Experimental trial not 
ethical, feasible, or too expensive 
Less expensive 
Can't assess 
causality, Can't 
eliminate all threats to 
validity 
adapted from Essentials of Epidemiology in Public Health (Aschengrau & Seage, 2008) and The Use and 
Interpretation of Quasi-experimental Studies in Infectious Disease (Harris et al., 2004) 
 
 
Table 2: Types of Observational studies 
Type of Study Indication(s) for use Pros Cons 
Case-Control 
Little is known about the disease, 
evaluate multiple exposures, disease 
is rare or has a log induction and latent 
period, exposure data are costly, 
population is dynamic 
Less expensive, Fewer 
subjects required 
Greater chance of 
bias, Can't infer 
temporal relationship 
between exposure 
and disease 
Cohort 
Little is known about the exposure, 
Evaluate many effects of an exposure, 
Exposure is rare, Underlying 
population is fixed 
Less expensive, High 
quality data in prospective 
study, Can utilize records in 
retrospective study 
Can't infer temporal 
relationship between 
exposure and disease 
Cross 
Sectional 
Examine associations at a single time 
point 
Generalizability, Low cost 
Can't infer temporal 
relationship between 
exposure and disease 
Ecologic 
Examine rates of disease to population 
level factors 
Low cost, Wide range of 
exposures 
Ecological fallacy, 
Paucity of information 
on variables 
adapted from Essentials of Epidemiology in Public Health (Aschengrau & Seage, 2008) 
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Complexity must be balanced with accuracy. Industrial regulations often drive 
clinical trial design, leading to complex assortments of data points required for 
evaluation (Clinpace, 2014). These complex trials are often labor intensive on study 
staff, ultimately resulting in protocol deviations and ambiguity of data. To combat this 
issue, the Clinical Trials Transformation Initiative(CTTI), a public-private collaborative 
which advocates for measures to increase the quality of clinical trials, has put forth a 
large simple trials project (Eapen, Lauer, & Temple, 2014). This project advocates for 
larger trials with fewer questions which will ultimately be less expensive and more 
efficient.  
 CTTI also maintains a Quality by Design toolkit available free of charge (CTTI, 
2016). This toolkit provides guidelines for conducting a quality clinical trial from 
conception to dissemination of results. The toolkit addresses protocol design, feasibility, 
patient safety, study conduct, study reporting, and third-party engagement. Protocol 
design comprises considerations for eligibility criteria, randomization, blinding, controls, 
data quantity, endpoints, data integrity and investigational products. Feasibility includes 
study and site feasibility and patient accrual. Patient safety contains informed consent, 
withdrawal and retention, safety reporting, and data monitoring. Study conduct includes 
training, data reporting and management, and statistical analysis. Study reporting 
considerations address dissemination of results. Third party engagement refers to 
delegation of responsibilities and collaborations. Because each clinical trial is unique, 
this tool is intended as a brainstorming document that provides considerations for 
design of a quality clinical trial (CTTI, 2016).  
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Assessment of Quality in Clinical Trials 
 Quality of clinical trials can be standardized and improved using appropriate 
tools. These tools are not only helpful for comparison of the quality amongst medical 
and public health trials, but can also serve as a guide for trial design. The Cochrane 
Handbook for systematic reviews of interventions suggests use of the Downs and Black 
instrument and the Newcastle-Ottawa scale for assessment non-randomized trials 
(Higgins & Green, 2011). The Downs and Black instrument provides a checklist in which 
a 0 or 1 is assigned to 27 parameters for a culminate score which can be utilized for 
both randomized and non-randomized clinical trials (Downs & Black, 1998). Within 
these 27 parameters are assessments of reporting quality, external validity, and internal 
validity. Analysis of reporting quality include: 
 statement of hypothesis 
 description of outcomes 
 characteristics of patients including those lost to follow up 
 interventions of interest and main findings 
 distribution of principle confounders 
 estimates of random variability 
 appropriate p-values defined apriori 
 reporting of all adverse events.  
Evaluation of external validity includes: 
 representativeness of the participants to the population 
 representativeness of the staff and study sites 
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 representativeness of the facilities and locations  
In addition, external validity includes ensuring that the target population for the 
treatment of interest is adequately represented. For example, if a treatment is likely to 
be primarily utilized in individuals older than 60, then the treatment should be tested in 
the elderly. If this treatment is instead tested in adults 18-45 then the results will not be 
generalizable to the population of interest, in this case individuals older than 60. 
Internal validity encompasses: 
 preventing bias by blinding of staff and participants 
 appropriateness of length of follow up 
 statistical analysis including adjustments for confounding variables 
 losses to follow up  
 power calculations 
 compliance with study protocol 
 accuracy and reliability of measurements 
 avoidance of selection bias 
 timing of recruitment and randomization  
 The Newcastle-Ottawa scale utilizes a star system to rate the quality of a trial 
and subdivides evaluation of non-randomized clinical trials into case-control and cohort 
(Wells et al., 2016). Unlike the Downs and Black instrument, the Newcastle-Ottawa 
scale does not evaluate reporting quality.  
Criteria evaluated for case-control studies include: 
 adequate case definition 
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 representativeness of population 
 appropriate selection and definition of controls 
 comparability of cases and controls 
 ascertainment of exposure, including method of ascertainment of exposure and 
non-response rate  
Cohort studies are evaluated based on the following criteria: 
 representativeness of exposed cohort 
 ascertainment of exposure 
 demonstration that outcome was not present at start 
 comparability of groups 
 assessment of outcome 
 appropriate length of follow up 
 adequacy of follow up  
Stars are awarded for positive responses to each question and tallied for comparison 
amongst trials.  
Numerous checklists and scales are available for assessing quality of 
randomized clinical trials (Moher et al., 1996). However, the Cochrane Handbook for 
systematic reviews of interventions suggest use of a domain based evaluation tool for 
assessing internal validity/bias of randomized clinical trials (Higgins & Green, 2011). 
This tool evaluates bias within domains of selection, performance, detection, attrition, 
reporting and other. Within the selection domain, the use of random sequence 
generators and concealment of allocation of interventions is reviewed. Random 
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sequence generators are tools by which patients are randomly assigned to treatment 
groups which are delineated in order to evaluate the treatment of interest. This random 
assignment is based on a randomly produced sequence, which is usually computer 
generated. Allocation concealment refers to the blinding of the random sequence from 
those assigning participants to treatment groups. Performance bias refers to the 
blinding of subjects and study staff, while detection bias refers to the blinding of 
assessors. Attrition bias is defined by completeness of the data regarding exclusion or 
removal of subjects from analysis. Reporting bias refers to reporting of selected specific 
outcomes. The final other bias category provides the reviewer with a category for 
concerns for bias not captured in the previous categories (Higgins & Green, 2011). This 
domain based tool focuses on internal validity but does not take into account 
appropriateness of analysis, design, and reporting.  
Numerous additional tools such as those presented above are available for 
evaluating validity of clinical trials. Each tool is useful in specific scenarios. However, no 
matter which tool is used, each evaluator provides a unique assessment. Assessments 
are typically constructed on information provided in a publication. As is detailed in the 
next section, standardized practices for reporting results of clinical trials are critical for 
comparative evaluations.    
Usability/Dissemination of Results 
Several initiatives have been put forth to standardize reporting of clinical trials. 
Section 801 of the Food and Drug Administration Amendments Act (FDAAA801) 
mandates registration of clinical trials conducted in the United States. Created in 2007, 
the website www.clinicaltrials.gov is a searchable database of registered clinical trials 
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that is accepted by the FDA in compliance with the FDAAA801 (NIH, 2016a). 
Clinicaltrials.gov entries are completed by the responsible party, either the sponsor of 
the trial or the principal investigator (NIH, 2016a). Information about clinical trials 
assessing drugs, biologics or devices in the United States are available through 
clinicaltrials.gov. This website generally does not register phase I trials, feasibility 
studies, behavioral trials, and non-interventional studies such as registries. Information 
available in the clinicaltrials.gov study record includes study status (i.e.: open, recruiting, 
completed), sponsor, collaborators, dates of entry and changes, purpose, eligibility, 
contacts, and study results.   
 CONSORT(Consolidated Standards of Reporting Trials) is a 25-item checklist 
and flow diagram designed to provide a guideline for reporting results of randomized 
clinical trials (CONSORT, 2016). CONSORT is recognized by many of the core medical 
journals including The Lancet and Journal of the American Medical Association 
(CONSORT, 2016). In addition, journals may require a CONSORT checklist upon 
submission of results of a clinical trial. The CONSORT checklist includes items typically 
found in a publication such as title, abstract, background, methods, results and 
discussion. Within these categories are more specific details regarding trial design, 
participants, interventions, outcomes, sample size, randomization, blinding, statistical 
methods, recruitment, data, harms, limitations, generalizability, registration, funding, etc. 
The full checklist can be found at www.consort-statement.org.  
 The RE-AIM initiative was originally developed to standardize reporting of public 
health interventions, but has since morphed into a resource to facilitate implementation 
of public health interventions (RE-AIM, 2016). RE-AIM stands for “Reach your intended 
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target population, Efficacy or effectiveness, Adoption by target staff, settings or 
institutions, Implementation consistency, costs and adaptation made during delivery, 
and Maintenance of intervention effects in individuals and settings over time” (RE-AIM, 
2016, para. 4). The RE-AIM.org website provides resources and tools for reporting and 
implementation of quality public health trials and interventions (RE-AIM, 2016). 
Resources include checklists for planning, literature reviews, and combining CONSORT 
and RE-AIM ideals. An online training module is also available. Standardizing reporting 
techniques will facilitate study comparison and aggregation into meta-analysis as well 
as impact usability of results.  
Good Clinical Practice: A Standard of Quality in Clinical Trials   
 Good clinical practice (GCP) guidelines also serve as a crucial reference for 
conducting quality clinical trials. GCP training is required by most if not all clinical trial 
funding entities. A number of GCP trainings are available including the Collaborative 
Institutional Training Initiative (CITI) training program and the National Institutes of 
Health (NIH) GCP training program among others (CITI, 2016; NIH, 2016d). GCP 
training ensures the integrity of a clinical trial. In the United States many of the GCP 
standards are based on the Belmont Report (United States, 1978), while the 
international standard is the Declaration of Helsinki (World Medical Association, 2013). 
These documents serve as reference tools for ensuring the protection of research 
subjects and clinical trial integrity. 
Generalizability of Clinical Trials 
Generalizability is one of the most important factors affecting validity and quality 
of a clinical trial because generalizability improves the external validity of the findings of 
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the trial. Factors that contribute to the generalizability of a study include selection of the 
study population and the study location. In order to ensure results of a clinical trial are 
generalizable to the larger population, care must be taken when defining inclusion and 
exclusion criteria or cases and non-cases while keeping in mind the ultimate target 
population. Efforts should be made to enroll subjects of varying race, ethnicity, income, 
socioeconomic status and when appropriate sex and age. Considerations for the 
hypothesis and disease under investigation are necessary. For example, a study of a 
novel treatment for sickle cell disease will likely enroll a majority of individuals who have 
been shown to have a high prevalence of the disease, such as persons of African 
descent. However, use of matching or balancing techniques when randomizing to 
treatment groups will prevent demographic factors from confounding results. For 
example, upon enrollment, age, sex, and ethnicity information can be incorporated into 
the randomization stratification so that when two white males between the ages of 50 
and 60, who are matched in terms of demographics are enrolled, one of these 
individuals will be randomized to treatment group A while the other is randomized to 
treatment group B.  
Initiating a clinical trial at multiple sites improves generalizability over a trial 
conducted at a single center. However, diversity among the sites should also be 
considered. For example, expanding study locations to include community based 
practices improves generalizability over a multi-center trial conducted exclusively at 
large academic research centers. Study sites are often chosen based on the 
investigators present at the site. Scientists become clinical trial investigators through a 
variety of ways. For example, physicians may apply for funding for investigator initiated 
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clinical trials. If a physician is not initiating their own trials, they may be approached to 
participate for a number of reasons including their being a scientific or opinion leader in 
a particular field; or because they have developed an infrastructure that has resulted in 
a history of high enrollments; or perhaps because their patient base is of particular 
interest. Physicians may also seek opportunities to participate studies via cooperative 
groups such as those sponsored by the National Cancer institute (NCI). In most cases 
clinical trial participants are enrolled via a medical professional, therefore engaging 
physicians and public health professionals in diverse care settings will promote 
generalizability. 
Replication of studies also impacts generalizability. For example, if a study 
uncovers an association in a narrow population and a second and third study find the 
same association in different populations, taken together these studies can provide 
evidence that the result is generalizable to the larger population. Ideally, all clinical trials 
would be conducted world-wide, but issues surrounding funding and logistics create 
significant limitations. In addition, in the case of devices and pharmaceuticals, 
regulatory agencies in different geographical locations have differing requirements for 
granting approval. Replication of studies also improves internal and external validity. In 
fact, multiple studies are required for FDA approval of new drugs.  
Barriers to Clinical Trials: Narrow Enrollment Criteria 
 Numerous barriers to clinical trial participation exist. Narrow enrollment criteria 
create a barrier for participation, however, focused enrollment criteria are often 
necessary for testing specific hypotheses, e.g., how a treatment affects patients with 
specific medical indication. The population under investigation must be clearly defined 
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in advance and eligibility should be based on this population. Often inclusion and 
exclusion criteria beyond the definition of the target population are related to patient 
safety. For example, if a drug is known to negatively impact heart function then 
individuals with already reduced heart function would be excluded for safety reasons. 
Pregnant and lactating women are often excluded from trials for similar reasons in that 
safety of interventions for unborn and neonatal children are unknown. Ultimately, the 
goals of eligibility criteria are not directed at generalizability; instead they are more often 
focused on improving internal validity, by limiting attrition, and improving protocol 
compliance, and reliability of results. Similar considerations for populations are 
necessary when defining cases in a case-control or cohort study. Cases must be well 
defined in order for analysis to reveal associations. If case definitions are too broad, 
individuals who do not truly have the disease will be captured diluting the possibility of 
uncovering a cause. If a case definition is too narrow, then the number of cases may be 
too few to identify potential causes.   
Barriers to Clinical Trials: Opportunity 
Another important barrier to clinical trial participation is lack of access. Access to 
clinical trials is influenced by a number of factors including the types of studies offered 
at an institution, location/proximity to a treatment center, and income/financial burden. 
As patients and family members become educated with respect to the illness in 
question, these individuals may search for clinical trials related to their disease. If a 
study is not offered at the patient’s primary treating institution, they may choose to 
continue with standard of care rather than change physicians (IOM, 2010). Availability of 
clinical trials is directly related to provider interest. In general, providers at academic 
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institutions are more likely to be conducting clinical trials as funded research. This 
research is often a component of their performance evaluations, since funded trials 
ensure adequate finances for their salaries and also meet academic publication 
requirements for promotion. Community physicians are less likely to participate in 
research due to challenges related to time, lack of infrastructure to support trials, and in 
some cases financial disincentives (IOM, 2010). Physicians have noted concerns that 
patient relationships may be negatively influenced by the uncertainty of randomization in 
a clinical trial (Unger, Cook, Tai, & Bleyer, 2016). Lack of opportunity for clinical trials in 
the United States is also influenced by the structure of the health care system. In 
countries with nationalized health care systems, clinical research takes place in a 
variety of sites (IOM, 2010). As mentioned previously, diversity in participating 
geographic locations and types of care centers promotes generalizability.  
Narrow enrollment criteria and lack of availability of appropriate clinical trials are 
barriers that apply to all populations. In fact, a recent study suggests that availability of 
and eligibility for trials are significant hurdles, regardless of demographics (Rearden, 
Hanlon, Ulrich, Brooks-Carthon, & Sommers, 2016). This study utilized a cross-
sectional matched design, which improves internal and external validity in a non-
experimental study, to determine eligibility and opportunity for participation in cancer 
related clinical trials. The authors matched Non-Hispanic white subjects with previously 
identified black or Hispanic subjects. Their results indicate that while socioeconomic 
status, education level, and insurance status differed between black or Hispanic and 
Non-Hispanic whites, no significant difference in opportunity or eligibility was present 
(Rearden et al., 2016). The authors also note that opportunity and eligibility for trial 
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increases for patients with late stage disease. This study was conducted at a large 
public urban institution supporting pharmaceutical, cooperative group, and investigator 
initiated trials and thus generalizability to other institutions, particularly in rural areas, is 
questionable. Nonetheless, narrow inclusion and exclusion criteria and lack of available 
trials remain substantial limitations to participation for all populations.   
Barriers to Clinical Trials: Financial Strain 
Participation in clinical trials often requires additional visits to the medical facility 
on top of standard of care visits. If an individual lives far from the treatment center or 
has issues surrounding transportation, they may be unable to make additional trips 
required. Lack of proximity to available trials can become a financial burden for clinical 
trial participants. Individuals in low socioeconomic brackets are disproportionately 
affected by financial barriers. One way to alleviate financial barriers is to cover excess 
costs associated with participation (Unger, Gralow, Albain, Ramsey, & Hershman, 
2016). Local institutions are recognizing financial burdens and implementing strategies 
to combat financial barriers (Nipp et al., 2016). One institution implemented a Cancer 
Care Equity Program which provided financial assistance to cancer patients as well as 
patient navigation and community outreach to promote awareness of options for care 
including clinical trials (Nipp et al., 2016). A recent study of the effects of this program 
on clinical trial participation documented that clinical trial participants eligible for 
financial assistance were more likely to be concerned about travel, lodging, and medical 
costs, health insurance, transportation, schedule, and to be bothered by overall financial 
concerns associated with clinical trial participation (Nipp et al., 2016). Despite these 
concerns, the implementation of the Cancer Care Equity Program increased clinical trial 
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participation by approximately 19 patients per month (Nipp et al., 2016). This study 
highlights the financial barrier, which is influenced by proximity, associated with 
participation in cancer clinical trials.  
Underrepresented Populations 
Clinical trial populations have historically excluded important segments of the 
population who may benefit from the novel treatments under investigation. In fact, 
clinical trial participation is dominated by white males. Underrepresented populations 
include: 
 The elderly: Two thirds of cancer patients are over the age of 65 yet they 
only comprise one third of the clinical trial participants (Clinpace, 2014; 
Lewis et al., 2003). 
 Adolescents and young adults: Only 10% of 15-19 year olds participate in 
cancer related clinical trials, in contrast 60% of children less than 15 
participate (Clinpace, 2014). Adolescents, 15-19 year olds, tend to fall into 
a clinical trial gap as adult trials require enrollees to be over the age of 18. 
 Non-white racial and ethnic groups: White individuals have dominated 
enrollment in NCI sponsored clinical trials, with greater than 70% in 2008 
(Pinn, Roth, Bates, Wagner, & Jarema, 2009). 
 Women: Women are underrepresented in studies of lung and colorectal 
cancer (Clinpace, 2014). 
 Low income: Low income patients are less likely to enroll (Unger, Gralow, 
et al., 2016). 
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 Rural: Although major medical centers located in urban areas provide the 
greatest opportunities for clinical trial participation, suburban populations 
are most represented in clinical trials. Representation of rural populations 
is deficient (Clinpace, 2014). 
 Uninsured: Despite cancer clinical trials often providing free or reduced 
costs for participants, uninsured individuals are less likely to participate 
(Colon-Otero et al., 2008). 
This list is not exhaustive. Underrepresented populations are often specific to the type 
of study and treatment. For example, underrepresentation in trials investigating new 
drugs is common due to expenses required to capture a generalizable population and 
regulations designed to protect certain populations. Epidemiologic studies often provide 
broader representation with respect to underrepresented populations compared to 
randomized controlled trials.  
Barriers for Underrepresented Populations 
 Even with efforts to boost enrollment (NIH, 2016e) barriers continue to exist for 
underrepresented populations. As mentioned previously teenagers 15-19 years of age 
are historically underrepresented in clinical trials. Despite statements from governments 
worldwide against age restrictions, age cutoffs remain in place largely due pediatric vs. 
adult funding sources and departmental delineations (Fern, Lewandowski, Coxon, 
Whelan, & National Cancer Research Institute Teenage and Young Adult Clinical 
Studies Group, 2014). In addition, Institutional Review Boards (IRB), restrict the 
inclusion of vulnerable populations, including children. Although safety factors must be 
considered in trial design, specific exclusion of age groups is often unwarranted. Age 
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restrictions related to legal consent can be circumvented by inclusion of parent/guardian 
consent provision. A systematic review of clinical trials enrollment in Britain found no 
scientific basis for age related inclusion or exclusion criteria (Fern et al., 2014). More 
recently several countries have released initiatives aimed at increasing enrollment of 
teenagers in clinical trials. In the United States, this initiative, championed by the NCI 
and the US Children’s Oncology Group, allows for lowering of age limits for adult trials 
and raising of age limits for traditionally pediatric studies (Bleyer, 2007). Non-cancer 
related initiatives such as the adolescent trials network for HIV/AIDS interventions have 
also been created (ATN, 2014). Lack of inclusion of adolescents in clinical trials leaves 
physicians in ethical quagmires regarding safety of treatment options for this age group.  
 Similar to teenagers, underrepresentation of elderly individuals (>65 years of 
age) in clinical trials affects treatment decisions. While individuals over 65 comprise 
65% of new cancer diagnosis, the elderly only make up 25% of trial participants 
(Denson & Mahipal, 2014). Elderly individuals are disproportionally susceptible to 
exclusion criteria surrounding performance status as these individuals are more likely to 
experience co-morbidities affecting this parameter. Elderly patients are also more likely 
to experience barriers related to access such as transportation, finances, and a lack of 
autonomy (Denson & Mahipal, 2014). In 1974, the National Institute on Aging was 
created to investigate aging related health issues. Unfortunately, due to the specificity of 
funding allocations, this entity does little to promote age diversity in clinical trials. 
However, guidelines released by the Food and Drug Administration (FDA) specifically 
address inclusion of older individuals in clinical trials (FDA, 1994). These guidelines 
emphasize the importance of inclusion of this group in trials where the elderly are likely 
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to be the primary end user of the treatment being tested. In order to meet these 
guidelines, trials of drugs likely to be used by elderly populations are beginning to 
stratify age groups in order to obtain representative populations, including groups >75 
years of age. Nonetheless, the lack of older individuals in clinical trials prevents 
availability of evidence based practices for treating this population.     
 Despite greater burden of diseases such as diabetes and alcoholism and 
elevated rates of cancer deaths, indigenous people are less likely to participate in 
clinical trials (Sprague, Russo, LaVallie, & Buchwald, 2013). Indigenous people site 
barriers such as lack of access, distrust of medical professionals, lack of understanding 
of materials and procedures (Glover et al., 2015; Sprague et al., 2013). In the United 
States, additional barriers to trial participation exist due to the need for approval by 
appropriate tribal entities, including the Indian Health Services(IHS) IRB (IHS, 2016b). 
The IHS, a division within the Department of Health and Human Services, was 
established to promote the health of Native Americans and Native Alaskans. The goal of 
the IHS is to ensure “comprehensive, culturally acceptable personal and public health 
services are available and accessible to American Indian and Alaska Native people” 
(IHS, 2016a, para. 2) As with many ethnic and racial minority groups, consideration of 
cultural norms can facilitate enrollment. For example, relationship building, use of 
culturally appropriate study design and study materials, employing indigenous study 
staff, and use of targeted recruitment techniques have been utilized to enhance study 
participation (Glover et al., 2015).   
 Similar to indigenous peoples, African Americans are disproportionately affected 
by cancer (Ahaghotu, Tyler, & Sartor, 2016; Aizer et al., 2014). However, African 
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Americans continue to be underrepresented in clinical trials (Ford et al., 2008). Barriers 
to enrollment to clinical trials for African Americans are similar to other minorities and 
include socioeconomic barriers, lack of awareness, and lack of willingness to 
participate/mistrust. The mistrust of clinical trials in this community is particularly 
pertinent given the infamous Tuskegee syphilis experiment. Despite the availability of 
treatment, the US Public Health Service studied the natural progression of syphilis in 
African Americans in Alabama during the 1930 to 1970s (Hughes, Sellers, Fraser, 
Knight, & Areghan, 2003). In fact, a qualitative focus group based study found that the 
Tuskegee syphilis experiment still resonated with African American cancer patients, 
especially those old enough to be alive when the study was conducted (Hughes, Knight, 
Fraser Jr., & Teague, 2005). Strategies to increase enrollment of African Americans in 
clinical trials include engaging African Americans using culturally sensitive materials and 
existing community groups (Ahaghotu et al., 2016). For example, during my MPH 
practicum a member of FirstHealth of the Carolinas clinical trials team conducted a well-
received informational presentation at a local meeting of the National Association for the 
Advancement of Colored People (NAACP). Additional approaches to increase 
engagement include recruitment of African American and community based physicians 
to serve as investigators and increasing physician awareness of cultural sensitives 
(Ahaghotu et al., 2016). Finally, specific targeting of hospitals and health care systems 
that serve African American communities will increase access.  
 In the United States, Hispanic Americans are also underrepresented in clinical 
trials. A recent qualitative study of Hispanic Americans in Texas uncovered 4 themes 
related to barriers to clinical trials; fears, knowledge (or lack of knowledge) of clinical 
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trials, perceived benefits, and incentives to participation (Arevalo et al., 2016). This 
study conducted focus groups in both English and Spanish, highlighting the need for 
clinical trial materials in Spanish as well as Spanish speaking staff. Unique to this 
population, fears of deportation were also expressed by participants in this study 
(Arevalo et al., 2016). Similar to other underrepresented groups, strategies to overcome 
these barriers include, engaging local community groups and trusted physicians, 
education of the purpose and expectations of a clinical trial as well as transparency 
regarding compensation and risk/benefits.     
Similar to Hispanic Americans, representation of Asian Americans in clinical trials 
is disproportionately low (Ma et al., 2014). A recent qualitative study observed that 
unlike other minority groups, Asian Americans place less weight on cultural barriers and 
more emphasis the hope for a treatment/cure (Ma et al., 2014). Although similar themes 
of physician trust are noted, focus group participants also emphasized the importance of 
balancing risks and benefits. The primary care physician plays a role in Asian American 
enrollment in clinical trials. As such, expertise is respected and physicians should utilize 
open communication to explain the benefits. Physicians should also be mindful of 
stigmas in the Asian community associated with the word trial, and instead use words 
such as research or study (Tran, 2015). Asians tend to be selfless and prefer not to 
disrupt their family. However, incentives and reminding potential participants that their 
role in the trial will benefit others are relevant motivators (Tran, 2015). 
Vulnerable populations are often underrepresented in clinical trials usually due to 
special regulations and IRB protections intended to guard these populations from harm. 
While special considerations are made for vulnerable populations such as children, 
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pregnant women, prisoners, and students, attention should be paid to balance the 
integrity of the trial. Trials should not discriminate against vulnerable populations but 
care must be taken to avoid exploitation as well. In this case the IRB serves to oversee 
the inclusion of these vulnerable populations. However, IRB protections of vulnerable 
populations may limit generalizability if they become a barrier to the conduct of a clinical 
trial. For example, a sponsor may choose to exclude vulnerable populations to avoid 
additional IRB paperwork and oversite. If vulnerable populations are excluded from 
trials, then evidence based practices for these individuals will continue to be lacking.  
Discussion   
Impact of Barriers on Results 
Barriers to clinical trial participation directly influence external validity and 
generalizability of trial results. If clinical trial enrollment is not representative of the 
population of interest, interpretation can be flawed and translation of results to clinical 
practice delayed. Safety of drugs and interventions is of particular concern. For 
example, if a trial population is comprised entirely of adults, physicians may be reluctant 
translate these results into their practices for use by pediatric patients. Careful analysis 
of generalizability must be considered when extrapolating results of trials to the target 
population. Barriers are often impossible to avoid and different studies may face 
different barriers to enrollment. The use of systematic reviews to aggregate data from 
multiple studies may be utilized to determine generalizability and alleviate concern as 
well as guide evidence based practices for the wider population. 
Recommendations to Address Barriers to Clinical Trial Participation 
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In 2016, the National Academy of Sciences published the proceedings of a 
workshop entitled “Strategies for Ensuring Diversity, Inclusion and Meaningful 
Participation in Clinical Trials” (National Academies of Medicine, Science and 
Engineering, 2016). This report put forth best practices and policies for ensuring 
diversity in clinical trials. Suggestions include:  
 Population-specific recruitment strategies and sites 
 Funding and institutional support for targeted infrastructure 
 Feedback mechanisms for recruitment goals 
 Sensitivity to socioeconomic factors 
 Centralized disparities committees 
 Workforce and research team diversity 
 Cultural competency training for research teams 
 Engaging with community stakeholders 
 Seeking community involvement  
These suggestions can be amalgamated into two major categories: boosting 
recruitment of diverse populations and policies/initiatives that enhance generalizability. 
Employing staff representative of the target population promotes relatability for 
participants. Efforts to recruit representative populations to clinical trials can be 
enhanced by engaging community stakeholders and organizations whose members are 
typically underrepresented in clinical trials. For example, outreach to faith based 
organizations is one approach to enhancing community engagement. The authors of 
one study partnered with faith based organizations to target minorities for Project 
SCALE (Small Changes and Lasting Effects), a randomized weight loss intervention 
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(Hippolyte, Phillips-Caesar, Winston, Charlson, & Peterson, 2013). This group found 
that working directly with the leader of the faith based organization was critical. In 
addition, the approach of the leader should be tailored to the size of the organization. In 
one instance the faith based leader participated in the trial. In this case, leading by 
example was particularly helpful for motivating study participants and reducing fear, 
stigma, and apprehension. In addition to faith based organizations, outreach to other 
local community centers and civic groups, including local chapters of the NAACP, senior 
centers, Latino, Asian, or Native American civic organizations is worthwhile. Each 
community is different and, thus, the appropriate partners must be evaluated on a case 
by case basis. Nonetheless, building trust through community partnerships is important 
for diversifying clinical trial enrollment and enhancing generalizability.   
 Recruitment efforts can also be boosted by engaging community and minority 
physicians. The doctor patient relationship promotes trust. In fact, a study found that 
patients were more likely to participate in a clinical trial if the trial is recommended by 
their treating physician (Walsh & Sheridan, 2016). Therefore, recruiting physicians, who 
serve underrepresented populations, can increase participation by these populations 
and ultimately enhance generalizability. One important consideration is that the 
physician must be willing and able to provide the effort required to serve as an 
investigator. In the case of pharmaceutical trials, physicians are incentivized with 
monetary compensation. However, often physicians who participate in clinical trials 
have a history of involvement. Therefore, efforts to recruit new physician investigators 
are required. One possible way to engage new physicians would be to enhance 
exposure to clinical trials during training via residency or fellowship programs. Exposure 
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during training would embed trials in the physician culture, leading to graduates that are 
more likely to suggest a clinical trial to their patients.  
 Another important approach for improving diversity in clinical study participants is 
through incentives and initiatives put forth by the funding agencies. The majority of 
policies and initiatives that promote clinical trial participation in the United States are put 
forth through the NIH. The NIH Revitalization Act of 1993, supported by the Public 
Health Service Act sec. 492B, 42 U.S.C. sec. 289a-2, “ensure[s] the inclusion of women 
and minority groups in clinical research…in a manner that is appropriate to the scientific 
question under study” (NIH, 2016e, para. 1). This policy applies to all NIH sponsored 
research. In addition to the NIH, the FDA has also put forth a policy to ensure that sex 
differences are understood with regards to disease therapy (FDA, 2016). The NIH 
funded office of Research on Women’s Health promotes the appropriate representation 
of women in clinical trials in addition to emphasizing the importance of understanding 
sex differences (NIH, 2016b). Sex differences, with respect to drug response, have 
been documented. However, the extent to which these differences are consequential to 
health are unknown. Therefore, the sex disparity among clinical trial participants  
remains controversial (Berlin & Ellenberg, 2009).  
Other NIH based initiatives aimed at diversifying clinical trial participation include 
the aforementioned ATN and adolescent oncology initiative as well as, the EMPACT 
consortium (Enhancing Minority Participation in Clinical Trials), and the NIH Community 
Oncology Research Program (NCORP). The EMPACT consortium, formed in 2009, is 
funded through the National Institute on Minority Health and Health Disparities. The goal 
of the EMPACT consortium is to “increase recruitment and retention of racial/ethnic 
minorities into therapeutic clinical trials with the ultimate goal of reducing cancer-related 
26 
 
health disparities” (@EMPaCTHealth, 2012, para. 1). The EMPACT consortium offers 
resources and training courses specifically aimed at recruiting minorities to clinical 
research. Local groups supplement national initiatives to increase minority participation 
in clinical research. One example of this type of group is HealthStreet, a community 
engagement program based out of the University of Florida (HealthStreet, 2016). The 
mission of HealthStreet is to “to reduce disparities in healthcare and research” 
(HealthStreet, 2016, para. 3). HealthStreet seeks not only to build trust in the 
community and to link individuals to care but also introduce them to clinical research. 
HealthStreet maintains and database of individuals who are willing to participate in 
clinical trials, and researchers may utilize this database when seeking clinical trial 
participants. Over 3300 people have been linked to research studies through 
HealthStreet (HealthStreet, 2016).  
The goal of NCORP “is to bring cancer clinical trials (cancer control, prevention, 
screening, treatment, and imaging), as well as cancer care delivery research (CCDR), 
to individuals in their own communities” (NIH, 2016c, para. 2). A variety of NCORPs 
exist in the United States, including 34 Community Clinical Oncology programs (CCOP), 
7 research bases, and 12 Minority/Underserved programs. These programs bring 
access to NCI clinical trials to community oncology centers, which typically do not 
support investigator initiated trials. For example, FirstHealth of the Carolinas in 
Pinehurst, NC is a member of the Southeast Clinical Oncology Research (SCOR) 
Consortium NCORP (See Figure 1). Based in Winston Salem, North Carolina, SCOR is 
a CCOP comprised of 22 community sites across the southeast including North and 
South Carolina, Georgia, Tennessee and Virginia (SCOR, 2016). NCORPs not only 
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allow patients to remain at their primary treating institutions which overcomes the 
access barrier, but also provides generalizability by promoting research at non-
traditional institutions. Both local and national initiatives are critical to promoting clinical 
trial participation among historically underrepresented individuals, including vulnerable 
populations. Ultimately these efforts can increase generalizability, and improve the 
external validity of clinical research. 
 
Figure 1: Map of SCOR participants in North Carolina. Blue circles are Community Clinical Oncology Programs, 
Green Triangles are Minority Community Sites, Blue diamonds are research bases(under red circles over Winston 
Salem, NC), and red circles are component/subcomponent sites of SCOR in North Carolina. Map taken from 
https://ncorp.cancer.gov/findasite/map.html.  
 
Conclusions and Future Research 
 Generalizability of clinical trials is central to evidenced based medicine and is 
critical to enhance the translation of clinical research into practice for the broadest 
population and especially those who are in greatest need. A number of factors influence 
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generalizability. In order for clinical trials to have maximum external validity, the patient 
population included in studies must be representative of the population of interest. While 
the randomized controlled trial is the gold standard, use of other epidemiological 
methods may provide adequate information; however, both types of studies are subject 
to threats to external validity due to lack of diversity in study populations. A balance 
between complexity and validity must be achieved. Quasi-experimental and 
demographically matched designs provide opportunities for high generalizability at costs 
lower than that of randomized controlled trials. Replication of studies also supplements 
original data and promotes generalizability.   
 This paper has discussed barriers to enrollment for underrepresented and 
vulnerable populations. An important consideration that affects the conduct of clinical 
trials in general is the important and necessary regulatory process; which sometimes 
also leads to barriers to participation. For example, conducting clinical trials at 
specialized institutions, such as jails or schools, often requires additional IRB oversite. 
Sponsors may decide to avoid conducting trials at specialized institutions due to 
additional IRB requirements. However, increased use of approved centralized IRBs 
provides the opportunity to consolidate oversite while maintaining integrity of the 
research process.  
While generally applicable only to pharmaceutical and device trials, regulations 
set forth by each individual country may weaken generalizability if a company chooses 
to focus their resources on one market. However, recently there have been initiatives 
that improve the efficiency of global clinical research such that global trials become the 
standard. The formation of the International Council for Harmonization of Technical 
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Requirements for Pharmaceuticals for Human Use (ICH) has sought to address this 
barrier. Although ICH is comprised of representatives from the United States, Europe, 
Japan, Canada, and Switzerland, many other nations recognize their authority, including 
Mexico, Australia and Russia among others (ICH, 2016). Regional and international 
entities, such as the World Health Organization and the Asian-Pacific Economic 
cooperation, are involved in the ICH as observers or members. The ICH provides 
training and guidelines for the development of new drugs and devices, but most 
importantly the ICH provides a “one stop shop” for regulatory approval. As additional 
entities recognize the ICH the approval process will become less of a barrier.  
As the United States becomes more culturally diverse and internationally 
conducted clinical trials become more feasible, the understanding of barriers to 
participation of all individuals is critical. Further research is required to identify 
successful strategies to overcome barriers unique to specific populations. In addition, 
the impact of IRB protections on vulnerable populations to enrollment in clinical trials 
needs further study. Future investigations are required ensure the balance of protection 
and incorporation of these populations. Protected populations should not go without 
novel interventions because effects of these interventions are unknown.  
Barriers to clinical trial participation influence generalizability of clinical trial 
results and are a direct threat to external validity. These barriers must be addressed to 
ensure safety and efficacy of best practices amongst all populations. Initiatives to break 
down barriers must be supported by funding agencies. In addition to efforts by 
regulatory and funding agencies, the entire research community needs greater 
awareness of barriers to diversity. Joint efforts are required by investigators, community 
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organizations, and academic institutions, to improve the translation of research into 
practice for all people, including the populations who will benefit the most from new 
treatments. 
In summary, greater leadership is required to enhance strategies that promote 
generalizability and external validity of clinical trials. For example, use of good 
communication skills and demonstrating cultural competence will facilitate building of 
relationships with community groups. In addition, endorsing vision statements that 
incorporate removal of barriers and promote inclusion of all persons will provide a clear 
message to patients and providers. Developing strong and diverse teams to overcome 
barriers at the funding, hospital, or practice level will enhance the likelihood of success. 
Guidelines presented here will facilitate the breakdown of barriers to clinical trial 
participation leading to diverse participation and greater generalizability so that all 
individuals will benefit from novel interventions.  
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